nodes	percent_of_prediction	percent_of_DWPC	metapath
Paliperidone—CYP3A5—Tamoxifen—pancreatic cancer	0.0549	0.148	CbGbCtD
Paliperidone—CYP3A5—Erlotinib—pancreatic cancer	0.0467	0.126	CbGbCtD
Paliperidone—CYP3A5—Irinotecan—pancreatic cancer	0.0422	0.114	CbGbCtD
Paliperidone—CYP2D6—Tamoxifen—pancreatic cancer	0.0337	0.0908	CbGbCtD
Paliperidone—CYP3A5—Docetaxel—pancreatic cancer	0.0309	0.0833	CbGbCtD
Paliperidone—CYP3A5—Sunitinib—pancreatic cancer	0.0308	0.0829	CbGbCtD
Paliperidone—CYP2D6—Erlotinib—pancreatic cancer	0.0286	0.0772	CbGbCtD
Paliperidone—CYP3A4—Tamoxifen—pancreatic cancer	0.0214	0.0577	CbGbCtD
Paliperidone—CYP3A4—Erlotinib—pancreatic cancer	0.0182	0.0491	CbGbCtD
Paliperidone—CYP3A4—Irinotecan—pancreatic cancer	0.0165	0.0443	CbGbCtD
Paliperidone—CYP2D6—Doxorubicin—pancreatic cancer	0.0141	0.0381	CbGbCtD
Paliperidone—CYP3A4—Docetaxel—pancreatic cancer	0.0121	0.0325	CbGbCtD
Paliperidone—CYP3A4—Sunitinib—pancreatic cancer	0.012	0.0323	CbGbCtD
Paliperidone—CYP3A4—Doxorubicin—pancreatic cancer	0.00899	0.0242	CbGbCtD
Paliperidone—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—pancreatic cancer	0.000204	0.000517	CcSEcCtD
Paliperidone—Jaundice—Epirubicin—pancreatic cancer	0.000203	0.000514	CcSEcCtD
Paliperidone—Urinary tract infection—Epirubicin—pancreatic cancer	0.000202	0.000513	CcSEcCtD
Paliperidone—Conjunctivitis—Epirubicin—pancreatic cancer	0.000202	0.000513	CcSEcCtD
Paliperidone—Dysuria—Doxorubicin—pancreatic cancer	0.000202	0.000512	CcSEcCtD
Paliperidone—Neutropenia—Doxorubicin—pancreatic cancer	0.000202	0.000512	CcSEcCtD
Paliperidone—Hypersensitivity—Fluorouracil—pancreatic cancer	0.000201	0.000509	CcSEcCtD
Paliperidone—Dry mouth—Docetaxel—pancreatic cancer	0.0002	0.000509	CcSEcCtD
Paliperidone—Upper respiratory tract infection—Doxorubicin—pancreatic cancer	0.0002	0.000509	CcSEcCtD
Paliperidone—Pollakiuria—Doxorubicin—pancreatic cancer	0.000199	0.000506	CcSEcCtD
Paliperidone—Asthenia—Gemcitabine—pancreatic cancer	0.000199	0.000504	CcSEcCtD
Paliperidone—Confusional state—Docetaxel—pancreatic cancer	0.000198	0.000503	CcSEcCtD
Paliperidone—Hepatobiliary disease—Epirubicin—pancreatic cancer	0.000197	0.000499	CcSEcCtD
Paliperidone—Anaphylactic shock—Docetaxel—pancreatic cancer	0.000196	0.000499	CcSEcCtD
Paliperidone—Oedema—Docetaxel—pancreatic cancer	0.000196	0.000499	CcSEcCtD
Paliperidone—Weight increased—Doxorubicin—pancreatic cancer	0.000196	0.000498	CcSEcCtD
Paliperidone—Epistaxis—Epirubicin—pancreatic cancer	0.000196	0.000497	CcSEcCtD
Paliperidone—Pruritus—Gemcitabine—pancreatic cancer	0.000196	0.000497	CcSEcCtD
Paliperidone—Infection—Docetaxel—pancreatic cancer	0.000195	0.000495	CcSEcCtD
Paliperidone—Weight decreased—Doxorubicin—pancreatic cancer	0.000195	0.000495	CcSEcCtD
Paliperidone—Sinusitis—Epirubicin—pancreatic cancer	0.000195	0.000495	CcSEcCtD
Paliperidone—Hyperglycaemia—Doxorubicin—pancreatic cancer	0.000195	0.000494	CcSEcCtD
Paliperidone—Diarrhoea—Irinotecan—pancreatic cancer	0.000194	0.000494	CcSEcCtD
Paliperidone—Agranulocytosis—Epirubicin—pancreatic cancer	0.000194	0.000492	CcSEcCtD
Paliperidone—Pneumonia—Doxorubicin—pancreatic cancer	0.000193	0.000491	CcSEcCtD
Paliperidone—Shock—Docetaxel—pancreatic cancer	0.000193	0.000491	CcSEcCtD
Paliperidone—Nervous system disorder—Docetaxel—pancreatic cancer	0.000193	0.000489	CcSEcCtD
Paliperidone—Pruritus—Fluorouracil—pancreatic cancer	0.000193	0.000489	CcSEcCtD
Paliperidone—Thrombocytopenia—Docetaxel—pancreatic cancer	0.000192	0.000488	CcSEcCtD
Paliperidone—Infestation NOS—Doxorubicin—pancreatic cancer	0.000192	0.000488	CcSEcCtD
Paliperidone—Infestation—Doxorubicin—pancreatic cancer	0.000192	0.000488	CcSEcCtD
Paliperidone—Tachycardia—Docetaxel—pancreatic cancer	0.000192	0.000487	CcSEcCtD
Paliperidone—Skin disorder—Docetaxel—pancreatic cancer	0.000191	0.000484	CcSEcCtD
Paliperidone—Bradycardia—Epirubicin—pancreatic cancer	0.00019	0.000482	CcSEcCtD
Paliperidone—Diarrhoea—Gemcitabine—pancreatic cancer	0.000189	0.000481	CcSEcCtD
Paliperidone—Dizziness—Irinotecan—pancreatic cancer	0.000188	0.000477	CcSEcCtD
Paliperidone—Jaundice—Doxorubicin—pancreatic cancer	0.000187	0.000476	CcSEcCtD
Paliperidone—Anorexia—Docetaxel—pancreatic cancer	0.000187	0.000475	CcSEcCtD
Paliperidone—Rhinitis—Epirubicin—pancreatic cancer	0.000187	0.000475	CcSEcCtD
Paliperidone—Urinary tract infection—Doxorubicin—pancreatic cancer	0.000187	0.000474	CcSEcCtD
Paliperidone—Conjunctivitis—Doxorubicin—pancreatic cancer	0.000187	0.000474	CcSEcCtD
Paliperidone—Diarrhoea—Fluorouracil—pancreatic cancer	0.000186	0.000473	CcSEcCtD
Paliperidone—Hypoaesthesia—Epirubicin—pancreatic cancer	0.000186	0.000471	CcSEcCtD
Paliperidone—Urinary tract disorder—Epirubicin—pancreatic cancer	0.000184	0.000468	CcSEcCtD
Paliperidone—Oedema peripheral—Epirubicin—pancreatic cancer	0.000184	0.000466	CcSEcCtD
Paliperidone—Hypotension—Docetaxel—pancreatic cancer	0.000184	0.000466	CcSEcCtD
Paliperidone—Connective tissue disorder—Epirubicin—pancreatic cancer	0.000183	0.000465	CcSEcCtD
Paliperidone—Urethral disorder—Epirubicin—pancreatic cancer	0.000183	0.000464	CcSEcCtD
Paliperidone—Hepatobiliary disease—Doxorubicin—pancreatic cancer	0.000182	0.000462	CcSEcCtD
Paliperidone—Epistaxis—Doxorubicin—pancreatic cancer	0.000181	0.00046	CcSEcCtD
Paliperidone—Vomiting—Irinotecan—pancreatic cancer	0.000181	0.000459	CcSEcCtD
Paliperidone—Sinusitis—Doxorubicin—pancreatic cancer	0.00018	0.000458	CcSEcCtD
Paliperidone—Dizziness—Fluorouracil—pancreatic cancer	0.00018	0.000457	CcSEcCtD
Paliperidone—Agranulocytosis—Doxorubicin—pancreatic cancer	0.000179	0.000455	CcSEcCtD
Paliperidone—Rash—Irinotecan—pancreatic cancer	0.000179	0.000455	CcSEcCtD
Paliperidone—Dermatitis—Irinotecan—pancreatic cancer	0.000179	0.000454	CcSEcCtD
Paliperidone—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	0.000179	0.000454	CcSEcCtD
Paliperidone—Headache—Irinotecan—pancreatic cancer	0.000178	0.000452	CcSEcCtD
Paliperidone—Insomnia—Docetaxel—pancreatic cancer	0.000178	0.000451	CcSEcCtD
Paliperidone—Paraesthesia—Docetaxel—pancreatic cancer	0.000176	0.000448	CcSEcCtD
Paliperidone—Vomiting—Gemcitabine—pancreatic cancer	0.000176	0.000447	CcSEcCtD
Paliperidone—Bradycardia—Doxorubicin—pancreatic cancer	0.000176	0.000446	CcSEcCtD
Paliperidone—Dyspnoea—Docetaxel—pancreatic cancer	0.000175	0.000445	CcSEcCtD
Paliperidone—Somnolence—Docetaxel—pancreatic cancer	0.000175	0.000443	CcSEcCtD
Paliperidone—Rash—Gemcitabine—pancreatic cancer	0.000175	0.000443	CcSEcCtD
Paliperidone—Dermatitis—Gemcitabine—pancreatic cancer	0.000174	0.000443	CcSEcCtD
Paliperidone—Eye disorder—Epirubicin—pancreatic cancer	0.000174	0.000442	CcSEcCtD
Paliperidone—Tinnitus—Epirubicin—pancreatic cancer	0.000174	0.000441	CcSEcCtD
Paliperidone—Headache—Gemcitabine—pancreatic cancer	0.000173	0.00044	CcSEcCtD
Paliperidone—Flushing—Epirubicin—pancreatic cancer	0.000173	0.000439	CcSEcCtD
Paliperidone—Cardiac disorder—Epirubicin—pancreatic cancer	0.000173	0.000439	CcSEcCtD
Paliperidone—Vomiting—Fluorouracil—pancreatic cancer	0.000173	0.000439	CcSEcCtD
Paliperidone—Rhinitis—Doxorubicin—pancreatic cancer	0.000173	0.000439	CcSEcCtD
Paliperidone—Dyspepsia—Docetaxel—pancreatic cancer	0.000173	0.000439	CcSEcCtD
Paliperidone—Hypoaesthesia—Doxorubicin—pancreatic cancer	0.000172	0.000436	CcSEcCtD
Paliperidone—Rash—Fluorouracil—pancreatic cancer	0.000172	0.000436	CcSEcCtD
Paliperidone—Dermatitis—Fluorouracil—pancreatic cancer	0.000171	0.000435	CcSEcCtD
Paliperidone—Decreased appetite—Docetaxel—pancreatic cancer	0.000171	0.000433	CcSEcCtD
Paliperidone—Headache—Fluorouracil—pancreatic cancer	0.000171	0.000433	CcSEcCtD
Paliperidone—Urinary tract disorder—Doxorubicin—pancreatic cancer	0.00017	0.000433	CcSEcCtD
Paliperidone—Oedema peripheral—Doxorubicin—pancreatic cancer	0.00017	0.000432	CcSEcCtD
Paliperidone—Gastrointestinal disorder—Docetaxel—pancreatic cancer	0.00017	0.000431	CcSEcCtD
Paliperidone—Connective tissue disorder—Doxorubicin—pancreatic cancer	0.00017	0.00043	CcSEcCtD
Paliperidone—Fatigue—Docetaxel—pancreatic cancer	0.000169	0.00043	CcSEcCtD
Paliperidone—Angiopathy—Epirubicin—pancreatic cancer	0.000169	0.00043	CcSEcCtD
Paliperidone—Urethral disorder—Doxorubicin—pancreatic cancer	0.000169	0.000429	CcSEcCtD
Paliperidone—Nausea—Irinotecan—pancreatic cancer	0.000169	0.000428	CcSEcCtD
Paliperidone—Immune system disorder—Epirubicin—pancreatic cancer	0.000168	0.000428	CcSEcCtD
Paliperidone—Mediastinal disorder—Epirubicin—pancreatic cancer	0.000168	0.000427	CcSEcCtD
Paliperidone—Pain—Docetaxel—pancreatic cancer	0.000168	0.000426	CcSEcCtD
Paliperidone—Constipation—Docetaxel—pancreatic cancer	0.000168	0.000426	CcSEcCtD
Paliperidone—Chills—Epirubicin—pancreatic cancer	0.000167	0.000425	CcSEcCtD
Paliperidone—Alopecia—Epirubicin—pancreatic cancer	0.000165	0.000418	CcSEcCtD
Paliperidone—Nausea—Gemcitabine—pancreatic cancer	0.000164	0.000417	CcSEcCtD
Paliperidone—Mental disorder—Epirubicin—pancreatic cancer	0.000163	0.000415	CcSEcCtD
Paliperidone—Erythema—Epirubicin—pancreatic cancer	0.000162	0.000412	CcSEcCtD
Paliperidone—Malnutrition—Epirubicin—pancreatic cancer	0.000162	0.000412	CcSEcCtD
Paliperidone—Feeling abnormal—Docetaxel—pancreatic cancer	0.000162	0.000411	CcSEcCtD
Paliperidone—Nausea—Fluorouracil—pancreatic cancer	0.000162	0.00041	CcSEcCtD
Paliperidone—Eye disorder—Doxorubicin—pancreatic cancer	0.000161	0.000409	CcSEcCtD
Paliperidone—Tinnitus—Doxorubicin—pancreatic cancer	0.000161	0.000408	CcSEcCtD
Paliperidone—Gastrointestinal pain—Docetaxel—pancreatic cancer	0.000161	0.000408	CcSEcCtD
Paliperidone—Flushing—Doxorubicin—pancreatic cancer	0.00016	0.000407	CcSEcCtD
Paliperidone—Cardiac disorder—Doxorubicin—pancreatic cancer	0.00016	0.000407	CcSEcCtD
Paliperidone—Flatulence—Epirubicin—pancreatic cancer	0.00016	0.000406	CcSEcCtD
Paliperidone—Tension—Epirubicin—pancreatic cancer	0.000159	0.000404	CcSEcCtD
Paliperidone—Dysgeusia—Epirubicin—pancreatic cancer	0.000159	0.000404	CcSEcCtD
Paliperidone—Nervousness—Epirubicin—pancreatic cancer	0.000158	0.0004	CcSEcCtD
Paliperidone—Back pain—Epirubicin—pancreatic cancer	0.000157	0.000399	CcSEcCtD
Paliperidone—Angiopathy—Doxorubicin—pancreatic cancer	0.000157	0.000397	CcSEcCtD
Paliperidone—Muscle spasms—Epirubicin—pancreatic cancer	0.000156	0.000396	CcSEcCtD
Paliperidone—Immune system disorder—Doxorubicin—pancreatic cancer	0.000156	0.000396	CcSEcCtD
Paliperidone—Mediastinal disorder—Doxorubicin—pancreatic cancer	0.000156	0.000395	CcSEcCtD
Paliperidone—Abdominal pain—Docetaxel—pancreatic cancer	0.000155	0.000394	CcSEcCtD
Paliperidone—Body temperature increased—Docetaxel—pancreatic cancer	0.000155	0.000394	CcSEcCtD
Paliperidone—Chills—Doxorubicin—pancreatic cancer	0.000155	0.000393	CcSEcCtD
Paliperidone—Vision blurred—Epirubicin—pancreatic cancer	0.000153	0.000388	CcSEcCtD
Paliperidone—Alopecia—Doxorubicin—pancreatic cancer	0.000153	0.000387	CcSEcCtD
Paliperidone—Mental disorder—Doxorubicin—pancreatic cancer	0.000151	0.000384	CcSEcCtD
Paliperidone—Ill-defined disorder—Epirubicin—pancreatic cancer	0.000151	0.000382	CcSEcCtD
Paliperidone—Malnutrition—Doxorubicin—pancreatic cancer	0.00015	0.000381	CcSEcCtD
Paliperidone—Erythema—Doxorubicin—pancreatic cancer	0.00015	0.000381	CcSEcCtD
Paliperidone—Anaemia—Epirubicin—pancreatic cancer	0.00015	0.000381	CcSEcCtD
Paliperidone—Agitation—Epirubicin—pancreatic cancer	0.000149	0.000379	CcSEcCtD
Paliperidone—Flatulence—Doxorubicin—pancreatic cancer	0.000148	0.000376	CcSEcCtD
Paliperidone—Tension—Doxorubicin—pancreatic cancer	0.000147	0.000374	CcSEcCtD
Paliperidone—Dysgeusia—Doxorubicin—pancreatic cancer	0.000147	0.000373	CcSEcCtD
Paliperidone—Malaise—Epirubicin—pancreatic cancer	0.000146	0.000372	CcSEcCtD
Paliperidone—Nervousness—Doxorubicin—pancreatic cancer	0.000146	0.00037	CcSEcCtD
Paliperidone—Vertigo—Epirubicin—pancreatic cancer	0.000146	0.00037	CcSEcCtD
Paliperidone—Syncope—Epirubicin—pancreatic cancer	0.000146	0.00037	CcSEcCtD
Paliperidone—Leukopenia—Epirubicin—pancreatic cancer	0.000145	0.000369	CcSEcCtD
Paliperidone—Back pain—Doxorubicin—pancreatic cancer	0.000145	0.000369	CcSEcCtD
Paliperidone—Hypersensitivity—Docetaxel—pancreatic cancer	0.000145	0.000367	CcSEcCtD
Paliperidone—Muscle spasms—Doxorubicin—pancreatic cancer	0.000144	0.000367	CcSEcCtD
Paliperidone—Palpitations—Epirubicin—pancreatic cancer	0.000143	0.000364	CcSEcCtD
Paliperidone—Loss of consciousness—Epirubicin—pancreatic cancer	0.000143	0.000362	CcSEcCtD
Paliperidone—Cough—Epirubicin—pancreatic cancer	0.000142	0.00036	CcSEcCtD
Paliperidone—Vision blurred—Doxorubicin—pancreatic cancer	0.000142	0.000359	CcSEcCtD
Paliperidone—Asthenia—Docetaxel—pancreatic cancer	0.000141	0.000358	CcSEcCtD
Paliperidone—Convulsion—Epirubicin—pancreatic cancer	0.000141	0.000357	CcSEcCtD
Paliperidone—Hypertension—Epirubicin—pancreatic cancer	0.00014	0.000356	CcSEcCtD
Paliperidone—Ill-defined disorder—Doxorubicin—pancreatic cancer	0.000139	0.000354	CcSEcCtD
Paliperidone—Pruritus—Docetaxel—pancreatic cancer	0.000139	0.000353	CcSEcCtD
Paliperidone—Anaemia—Doxorubicin—pancreatic cancer	0.000139	0.000352	CcSEcCtD
Paliperidone—Chest pain—Epirubicin—pancreatic cancer	0.000138	0.000351	CcSEcCtD
Paliperidone—Myalgia—Epirubicin—pancreatic cancer	0.000138	0.000351	CcSEcCtD
Paliperidone—Arthralgia—Epirubicin—pancreatic cancer	0.000138	0.000351	CcSEcCtD
Paliperidone—Agitation—Doxorubicin—pancreatic cancer	0.000138	0.00035	CcSEcCtD
Paliperidone—Anxiety—Epirubicin—pancreatic cancer	0.000138	0.00035	CcSEcCtD
Paliperidone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	0.000137	0.000348	CcSEcCtD
Paliperidone—Discomfort—Epirubicin—pancreatic cancer	0.000137	0.000347	CcSEcCtD
Paliperidone—Malaise—Doxorubicin—pancreatic cancer	0.000135	0.000344	CcSEcCtD
Paliperidone—Dry mouth—Epirubicin—pancreatic cancer	0.000135	0.000343	CcSEcCtD
Paliperidone—Vertigo—Doxorubicin—pancreatic cancer	0.000135	0.000343	CcSEcCtD
Paliperidone—Syncope—Doxorubicin—pancreatic cancer	0.000135	0.000342	CcSEcCtD
Paliperidone—Leukopenia—Doxorubicin—pancreatic cancer	0.000134	0.000341	CcSEcCtD
Paliperidone—Diarrhoea—Docetaxel—pancreatic cancer	0.000134	0.000341	CcSEcCtD
Paliperidone—Confusional state—Epirubicin—pancreatic cancer	0.000134	0.000339	CcSEcCtD
Paliperidone—Palpitations—Doxorubicin—pancreatic cancer	0.000133	0.000337	CcSEcCtD
Paliperidone—Anaphylactic shock—Epirubicin—pancreatic cancer	0.000133	0.000336	CcSEcCtD
Paliperidone—Oedema—Epirubicin—pancreatic cancer	0.000133	0.000336	CcSEcCtD
Paliperidone—Loss of consciousness—Doxorubicin—pancreatic cancer	0.000132	0.000335	CcSEcCtD
Paliperidone—Infection—Epirubicin—pancreatic cancer	0.000132	0.000334	CcSEcCtD
Paliperidone—Cough—Doxorubicin—pancreatic cancer	0.000131	0.000333	CcSEcCtD
Paliperidone—Shock—Epirubicin—pancreatic cancer	0.00013	0.000331	CcSEcCtD
Paliperidone—Convulsion—Doxorubicin—pancreatic cancer	0.00013	0.00033	CcSEcCtD
Paliperidone—Nervous system disorder—Epirubicin—pancreatic cancer	0.00013	0.00033	CcSEcCtD
Paliperidone—Dizziness—Docetaxel—pancreatic cancer	0.00013	0.00033	CcSEcCtD
Paliperidone—Thrombocytopenia—Epirubicin—pancreatic cancer	0.00013	0.000329	CcSEcCtD
Paliperidone—Hypertension—Doxorubicin—pancreatic cancer	0.00013	0.000329	CcSEcCtD
Paliperidone—Tachycardia—Epirubicin—pancreatic cancer	0.000129	0.000328	CcSEcCtD
Paliperidone—Skin disorder—Epirubicin—pancreatic cancer	0.000129	0.000327	CcSEcCtD
Paliperidone—Arthralgia—Doxorubicin—pancreatic cancer	0.000128	0.000325	CcSEcCtD
Paliperidone—Myalgia—Doxorubicin—pancreatic cancer	0.000128	0.000325	CcSEcCtD
Paliperidone—Chest pain—Doxorubicin—pancreatic cancer	0.000128	0.000325	CcSEcCtD
Paliperidone—Anxiety—Doxorubicin—pancreatic cancer	0.000127	0.000324	CcSEcCtD
Paliperidone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	0.000127	0.000322	CcSEcCtD
Paliperidone—Discomfort—Doxorubicin—pancreatic cancer	0.000126	0.000321	CcSEcCtD
Paliperidone—Anorexia—Epirubicin—pancreatic cancer	0.000126	0.000321	CcSEcCtD
Paliperidone—Dry mouth—Doxorubicin—pancreatic cancer	0.000125	0.000318	CcSEcCtD
Paliperidone—Vomiting—Docetaxel—pancreatic cancer	0.000125	0.000317	CcSEcCtD
Paliperidone—Rash—Docetaxel—pancreatic cancer	0.000124	0.000314	CcSEcCtD
Paliperidone—Hypotension—Epirubicin—pancreatic cancer	0.000124	0.000314	CcSEcCtD
Paliperidone—Dermatitis—Docetaxel—pancreatic cancer	0.000124	0.000314	CcSEcCtD
Paliperidone—Confusional state—Doxorubicin—pancreatic cancer	0.000124	0.000314	CcSEcCtD
Paliperidone—Headache—Docetaxel—pancreatic cancer	0.000123	0.000312	CcSEcCtD
Paliperidone—Anaphylactic shock—Doxorubicin—pancreatic cancer	0.000123	0.000311	CcSEcCtD
Paliperidone—Oedema—Doxorubicin—pancreatic cancer	0.000123	0.000311	CcSEcCtD
Paliperidone—Infection—Doxorubicin—pancreatic cancer	0.000122	0.000309	CcSEcCtD
Paliperidone—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	0.000121	0.000306	CcSEcCtD
Paliperidone—Shock—Doxorubicin—pancreatic cancer	0.000121	0.000306	CcSEcCtD
Paliperidone—Nervous system disorder—Doxorubicin—pancreatic cancer	0.00012	0.000305	CcSEcCtD
Paliperidone—Thrombocytopenia—Doxorubicin—pancreatic cancer	0.00012	0.000305	CcSEcCtD
Paliperidone—Insomnia—Epirubicin—pancreatic cancer	0.00012	0.000304	CcSEcCtD
Paliperidone—Tachycardia—Doxorubicin—pancreatic cancer	0.00012	0.000304	CcSEcCtD
Paliperidone—Skin disorder—Doxorubicin—pancreatic cancer	0.000119	0.000302	CcSEcCtD
Paliperidone—Paraesthesia—Epirubicin—pancreatic cancer	0.000119	0.000302	CcSEcCtD
Paliperidone—Dyspnoea—Epirubicin—pancreatic cancer	0.000118	0.0003	CcSEcCtD
Paliperidone—Somnolence—Epirubicin—pancreatic cancer	0.000118	0.000299	CcSEcCtD
Paliperidone—Anorexia—Doxorubicin—pancreatic cancer	0.000117	0.000297	CcSEcCtD
Paliperidone—Nausea—Docetaxel—pancreatic cancer	0.000117	0.000296	CcSEcCtD
Paliperidone—Dyspepsia—Epirubicin—pancreatic cancer	0.000117	0.000296	CcSEcCtD
Paliperidone—Decreased appetite—Epirubicin—pancreatic cancer	0.000115	0.000292	CcSEcCtD
Paliperidone—Hypotension—Doxorubicin—pancreatic cancer	0.000115	0.000291	CcSEcCtD
Paliperidone—Gastrointestinal disorder—Epirubicin—pancreatic cancer	0.000114	0.00029	CcSEcCtD
Paliperidone—Fatigue—Epirubicin—pancreatic cancer	0.000114	0.00029	CcSEcCtD
Paliperidone—Pain—Epirubicin—pancreatic cancer	0.000113	0.000288	CcSEcCtD
Paliperidone—Constipation—Epirubicin—pancreatic cancer	0.000113	0.000288	CcSEcCtD
Paliperidone—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	0.000112	0.000284	CcSEcCtD
Paliperidone—Insomnia—Doxorubicin—pancreatic cancer	0.000111	0.000281	CcSEcCtD
Paliperidone—Paraesthesia—Doxorubicin—pancreatic cancer	0.00011	0.000279	CcSEcCtD
Paliperidone—Dyspnoea—Doxorubicin—pancreatic cancer	0.000109	0.000277	CcSEcCtD
Paliperidone—Feeling abnormal—Epirubicin—pancreatic cancer	0.000109	0.000277	CcSEcCtD
Paliperidone—Somnolence—Doxorubicin—pancreatic cancer	0.000109	0.000277	CcSEcCtD
Paliperidone—Gastrointestinal pain—Epirubicin—pancreatic cancer	0.000108	0.000275	CcSEcCtD
Paliperidone—Dyspepsia—Doxorubicin—pancreatic cancer	0.000108	0.000274	CcSEcCtD
Paliperidone—Decreased appetite—Doxorubicin—pancreatic cancer	0.000107	0.000271	CcSEcCtD
Paliperidone—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	0.000106	0.000269	CcSEcCtD
Paliperidone—Fatigue—Doxorubicin—pancreatic cancer	0.000106	0.000268	CcSEcCtD
Paliperidone—Urticaria—Epirubicin—pancreatic cancer	0.000105	0.000267	CcSEcCtD
Paliperidone—Constipation—Doxorubicin—pancreatic cancer	0.000105	0.000266	CcSEcCtD
Paliperidone—Pain—Doxorubicin—pancreatic cancer	0.000105	0.000266	CcSEcCtD
Paliperidone—Abdominal pain—Epirubicin—pancreatic cancer	0.000105	0.000266	CcSEcCtD
Paliperidone—Body temperature increased—Epirubicin—pancreatic cancer	0.000105	0.000266	CcSEcCtD
Paliperidone—Feeling abnormal—Doxorubicin—pancreatic cancer	0.000101	0.000256	CcSEcCtD
Paliperidone—Gastrointestinal pain—Doxorubicin—pancreatic cancer	0.0001	0.000254	CcSEcCtD
Paliperidone—Hypersensitivity—Epirubicin—pancreatic cancer	9.76e-05	0.000248	CcSEcCtD
Paliperidone—Urticaria—Doxorubicin—pancreatic cancer	9.74e-05	0.000247	CcSEcCtD
Paliperidone—Abdominal pain—Doxorubicin—pancreatic cancer	9.69e-05	0.000246	CcSEcCtD
Paliperidone—Body temperature increased—Doxorubicin—pancreatic cancer	9.69e-05	0.000246	CcSEcCtD
Paliperidone—Asthenia—Epirubicin—pancreatic cancer	9.51e-05	0.000241	CcSEcCtD
Paliperidone—Pruritus—Epirubicin—pancreatic cancer	9.38e-05	0.000238	CcSEcCtD
Paliperidone—Diarrhoea—Epirubicin—pancreatic cancer	9.07e-05	0.00023	CcSEcCtD
Paliperidone—Hypersensitivity—Doxorubicin—pancreatic cancer	9.03e-05	0.000229	CcSEcCtD
Paliperidone—Asthenia—Doxorubicin—pancreatic cancer	8.8e-05	0.000223	CcSEcCtD
Paliperidone—Dizziness—Epirubicin—pancreatic cancer	8.76e-05	0.000222	CcSEcCtD
Paliperidone—Pruritus—Doxorubicin—pancreatic cancer	8.68e-05	0.00022	CcSEcCtD
Paliperidone—Vomiting—Epirubicin—pancreatic cancer	8.43e-05	0.000214	CcSEcCtD
Paliperidone—Diarrhoea—Doxorubicin—pancreatic cancer	8.39e-05	0.000213	CcSEcCtD
Paliperidone—Rash—Epirubicin—pancreatic cancer	8.36e-05	0.000212	CcSEcCtD
Paliperidone—Dermatitis—Epirubicin—pancreatic cancer	8.35e-05	0.000212	CcSEcCtD
Paliperidone—Headache—Epirubicin—pancreatic cancer	8.3e-05	0.000211	CcSEcCtD
Paliperidone—Dizziness—Doxorubicin—pancreatic cancer	8.11e-05	0.000206	CcSEcCtD
Paliperidone—Nausea—Epirubicin—pancreatic cancer	7.87e-05	0.0002	CcSEcCtD
Paliperidone—Vomiting—Doxorubicin—pancreatic cancer	7.8e-05	0.000198	CcSEcCtD
Paliperidone—Rash—Doxorubicin—pancreatic cancer	7.73e-05	0.000196	CcSEcCtD
Paliperidone—Dermatitis—Doxorubicin—pancreatic cancer	7.72e-05	0.000196	CcSEcCtD
Paliperidone—Headache—Doxorubicin—pancreatic cancer	7.68e-05	0.000195	CcSEcCtD
Paliperidone—Nausea—Doxorubicin—pancreatic cancer	7.28e-05	0.000185	CcSEcCtD
Paliperidone—CYP3A4—Metabolism—GCG—pancreatic cancer	9.96e-06	4.24e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—PIK3CB—pancreatic cancer	9.93e-06	4.23e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—CASP3—pancreatic cancer	9.91e-06	4.22e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling by GPCR—AKT1—pancreatic cancer	9.88e-06	4.21e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling by GPCR—PIK3CA—pancreatic cancer	9.87e-06	4.2e-05	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—KRAS—pancreatic cancer	9.85e-06	4.2e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—MMP9—pancreatic cancer	9.83e-06	4.19e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—CCND1—pancreatic cancer	9.8e-06	4.17e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—MMP9—pancreatic cancer	9.78e-06	4.16e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—PTEN—pancreatic cancer	9.77e-06	4.16e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—PIK3CB—pancreatic cancer	9.77e-06	4.16e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—PIK3CB—pancreatic cancer	9.75e-06	4.15e-05	CbGpPWpGaD
Paliperidone—CYP3A5—Metabolism—PIK3CB—pancreatic cancer	9.74e-06	4.15e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—PTEN—pancreatic cancer	9.72e-06	4.14e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—CTNNB1—pancreatic cancer	9.7e-06	4.13e-05	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—KRAS—pancreatic cancer	9.69e-06	4.13e-05	CbGpPWpGaD
Paliperidone—CYP3A5—Metabolism—PTGS2—pancreatic cancer	9.65e-06	4.11e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—CCND1—pancreatic cancer	9.64e-06	4.11e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—PIK3CB—pancreatic cancer	9.57e-06	4.07e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—CTNNB1—pancreatic cancer	9.55e-06	4.07e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—CXCL8—pancreatic cancer	9.54e-06	4.06e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling by GPCR—AKT1—pancreatic cancer	9.53e-06	4.06e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—MMP9—pancreatic cancer	9.51e-06	4.05e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling by GPCR—AKT1—pancreatic cancer	9.49e-06	4.04e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling by GPCR—HRAS—pancreatic cancer	9.48e-06	4.04e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—PTEN—pancreatic cancer	9.46e-06	4.03e-05	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—MYC—pancreatic cancer	9.44e-06	4.02e-05	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—TGFB1—pancreatic cancer	9.42e-06	4.01e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—CXCL8—pancreatic cancer	9.39e-06	4e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—SRC—pancreatic cancer	9.39e-06	4e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—CXCL8—pancreatic cancer	9.37e-06	3.99e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—MMP9—pancreatic cancer	9.36e-06	3.99e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—STK11—pancreatic cancer	9.36e-06	3.99e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling by GPCR—HRAS—pancreatic cancer	9.33e-06	3.97e-05	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—MYC—pancreatic cancer	9.32e-06	3.97e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling by GPCR—HRAS—pancreatic cancer	9.31e-06	3.96e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—PTEN—pancreatic cancer	9.31e-06	3.96e-05	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—TGFB1—pancreatic cancer	9.3e-06	3.96e-05	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—PIK3CA—pancreatic cancer	9.24e-06	3.94e-05	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—EGFR—pancreatic cancer	9.24e-06	3.93e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling by GPCR—AKT1—pancreatic cancer	9.23e-06	3.93e-05	CbGpPWpGaD
Paliperidone—DRD2—GPCR downstream signaling—AKT1—pancreatic cancer	9.22e-06	3.93e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—CXCL8—pancreatic cancer	9.19e-06	3.92e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Metabolism—PTEN—pancreatic cancer	9.19e-06	3.91e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling by GPCR—PIK3CA—pancreatic cancer	9.17e-06	3.91e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—VEGFA—pancreatic cancer	9.14e-06	3.89e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling by GPCR—HRAS—pancreatic cancer	9.13e-06	3.89e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—CASP3—pancreatic cancer	9.13e-06	3.89e-05	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—EGFR—pancreatic cancer	9.12e-06	3.88e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling by GPCR—AKT1—pancreatic cancer	9.08e-06	3.87e-05	CbGpPWpGaD
Paliperidone—HTR2A—GPCR downstream signaling—AKT1—pancreatic cancer	9.07e-06	3.86e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—SRC—pancreatic cancer	9.06e-06	3.86e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—STAT3—pancreatic cancer	9.05e-06	3.86e-05	CbGpPWpGaD
Paliperidone—HRH1—GPCR downstream signaling—AKT1—pancreatic cancer	9.05e-06	3.85e-05	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—PIK3CA—pancreatic cancer	9.05e-06	3.85e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—PIK3CG—pancreatic cancer	9.04e-06	3.85e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—NRAS—pancreatic cancer	9.03e-06	3.85e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—SRC—pancreatic cancer	9.02e-06	3.84e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—CASP3—pancreatic cancer	8.99e-06	3.83e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—CASP3—pancreatic cancer	8.97e-06	3.82e-05	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—TP53—pancreatic cancer	8.94e-06	3.81e-05	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—PIK3CA—pancreatic cancer	8.91e-06	3.79e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—CCND1—pancreatic cancer	8.89e-06	3.79e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—PIK3CB—pancreatic cancer	8.89e-06	3.79e-05	CbGpPWpGaD
Paliperidone—ADRA1A—GPCR downstream signaling—AKT1—pancreatic cancer	8.88e-06	3.78e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—VEGFA—pancreatic cancer	8.83e-06	3.76e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—CTNNB1—pancreatic cancer	8.8e-06	3.75e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—CASP3—pancreatic cancer	8.8e-06	3.75e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—VEGFA—pancreatic cancer	8.78e-06	3.74e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—SRC—pancreatic cancer	8.77e-06	3.73e-05	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—TP53—pancreatic cancer	8.76e-06	3.73e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—CCND1—pancreatic cancer	8.75e-06	3.73e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—STAT3—pancreatic cancer	8.74e-06	3.72e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—CCND1—pancreatic cancer	8.73e-06	3.72e-05	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—KRAS—pancreatic cancer	8.73e-06	3.72e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—PPARG—pancreatic cancer	8.73e-06	3.72e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—NRAS—pancreatic cancer	8.72e-06	3.71e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—STAT3—pancreatic cancer	8.7e-06	3.7e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—NRAS—pancreatic cancer	8.67e-06	3.69e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—CTNNB1—pancreatic cancer	8.66e-06	3.69e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—CTNNB1—pancreatic cancer	8.64e-06	3.68e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—SRC—pancreatic cancer	8.63e-06	3.68e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—MMP9—pancreatic cancer	8.63e-06	3.68e-05	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—TP53—pancreatic cancer	8.62e-06	3.67e-05	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—KRAS—pancreatic cancer	8.61e-06	3.67e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—PTEN—pancreatic cancer	8.58e-06	3.65e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—CCND1—pancreatic cancer	8.57e-06	3.65e-05	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—HRAS—pancreatic cancer	8.55e-06	3.64e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—CXCL8—pancreatic cancer	8.54e-06	3.64e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—VEGFA—pancreatic cancer	8.54e-06	3.64e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—MMP9—pancreatic cancer	8.49e-06	3.62e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling by GPCR—HRAS—pancreatic cancer	8.49e-06	3.61e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—CTNNB1—pancreatic cancer	8.48e-06	3.61e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—MMP9—pancreatic cancer	8.47e-06	3.61e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—STAT3—pancreatic cancer	8.46e-06	3.6e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—PTEN—pancreatic cancer	8.44e-06	3.6e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—NRAS—pancreatic cancer	8.44e-06	3.59e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—PTEN—pancreatic cancer	8.43e-06	3.59e-05	CbGpPWpGaD
Paliperidone—CYP3A5—Metabolism—PTEN—pancreatic cancer	8.42e-06	3.58e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—MYC—pancreatic cancer	8.41e-06	3.58e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—VEGFA—pancreatic cancer	8.41e-06	3.58e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—TGFB1—pancreatic cancer	8.39e-06	3.57e-05	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—HRAS—pancreatic cancer	8.37e-06	3.57e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling by GPCR—AKT1—pancreatic cancer	8.37e-06	3.56e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—STAT3—pancreatic cancer	8.32e-06	3.54e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—MMP9—pancreatic cancer	8.32e-06	3.54e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—NRAS—pancreatic cancer	8.3e-06	3.54e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—PTEN—pancreatic cancer	8.27e-06	3.52e-05	CbGpPWpGaD
Paliperidone—ADRA2A—GPCR downstream signaling—AKT1—pancreatic cancer	8.25e-06	3.51e-05	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—HRAS—pancreatic cancer	8.24e-06	3.51e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling by GPCR—AKT1—pancreatic cancer	8.24e-06	3.51e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—EGFR—pancreatic cancer	8.23e-06	3.5e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling by GPCR—AKT1—pancreatic cancer	8.22e-06	3.5e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—CASP3—pancreatic cancer	8.18e-06	3.48e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—MYC—pancreatic cancer	8.12e-06	3.46e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—TGFB1—pancreatic cancer	8.1e-06	3.45e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—MYC—pancreatic cancer	8.08e-06	3.44e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling by GPCR—AKT1—pancreatic cancer	8.07e-06	3.43e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—TGFB1—pancreatic cancer	8.06e-06	3.43e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—TYMS—pancreatic cancer	8.05e-06	3.43e-05	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—PIK3CA—pancreatic cancer	8.02e-06	3.41e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Metabolism—PIK3CA—pancreatic cancer	7.98e-06	3.4e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—CCND1—pancreatic cancer	7.96e-06	3.39e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—SRC—pancreatic cancer	7.96e-06	3.39e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—PIK3CD—pancreatic cancer	7.95e-06	3.38e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—EGFR—pancreatic cancer	7.94e-06	3.38e-05	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—PIK3CA—pancreatic cancer	7.91e-06	3.37e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—EGFR—pancreatic cancer	7.9e-06	3.37e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—CTNNB1—pancreatic cancer	7.88e-06	3.36e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—MYC—pancreatic cancer	7.86e-06	3.35e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—TGFB1—pancreatic cancer	7.84e-06	3.34e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—SRC—pancreatic cancer	7.83e-06	3.33e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—SRC—pancreatic cancer	7.81e-06	3.33e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—KRAS—pancreatic cancer	7.77e-06	3.31e-05	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—TP53—pancreatic cancer	7.76e-06	3.3e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—VEGFA—pancreatic cancer	7.75e-06	3.3e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—MYC—pancreatic cancer	7.73e-06	3.29e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—MMP9—pancreatic cancer	7.73e-06	3.29e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—TGFB1—pancreatic cancer	7.72e-06	3.29e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—EGFR—pancreatic cancer	7.69e-06	3.27e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—PTEN—pancreatic cancer	7.68e-06	3.27e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—STAT3—pancreatic cancer	7.67e-06	3.27e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—SRC—pancreatic cancer	7.67e-06	3.26e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—NRAS—pancreatic cancer	7.66e-06	3.26e-05	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—TP53—pancreatic cancer	7.65e-06	3.26e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—VEGFA—pancreatic cancer	7.63e-06	3.25e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—VEGFA—pancreatic cancer	7.61e-06	3.24e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—EGFR—pancreatic cancer	7.57e-06	3.22e-05	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—AKT1—pancreatic cancer	7.55e-06	3.22e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—STAT3—pancreatic cancer	7.55e-06	3.22e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—STAT3—pancreatic cancer	7.53e-06	3.21e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—NRAS—pancreatic cancer	7.53e-06	3.21e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—NRAS—pancreatic cancer	7.52e-06	3.2e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—KRAS—pancreatic cancer	7.5e-06	3.2e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling by GPCR—AKT1—pancreatic cancer	7.49e-06	3.19e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—VEGFA—pancreatic cancer	7.47e-06	3.18e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—KRAS—pancreatic cancer	7.47e-06	3.18e-05	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—HRAS—pancreatic cancer	7.42e-06	3.16e-05	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—AKT1—pancreatic cancer	7.39e-06	3.15e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—STAT3—pancreatic cancer	7.39e-06	3.15e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—NRAS—pancreatic cancer	7.38e-06	3.14e-05	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—HRAS—pancreatic cancer	7.32e-06	3.12e-05	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—AKT1—pancreatic cancer	7.28e-06	3.1e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—KRAS—pancreatic cancer	7.26e-06	3.09e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—KRAS—pancreatic cancer	7.15e-06	3.04e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—PIK3CA—pancreatic cancer	7.14e-06	3.04e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—MYC—pancreatic cancer	7.13e-06	3.04e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—SRC—pancreatic cancer	7.12e-06	3.03e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—TGFB1—pancreatic cancer	7.11e-06	3.03e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—MYC—pancreatic cancer	7.02e-06	2.99e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—MYC—pancreatic cancer	7e-06	2.98e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—TGFB1—pancreatic cancer	7e-06	2.98e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—TGFB1—pancreatic cancer	6.98e-06	2.97e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—EGFR—pancreatic cancer	6.97e-06	2.97e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—VEGFA—pancreatic cancer	6.94e-06	2.95e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—PIK3CB—pancreatic cancer	6.93e-06	2.95e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—TP53—pancreatic cancer	6.91e-06	2.94e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—PIK3CA—pancreatic cancer	6.89e-06	2.94e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—MYC—pancreatic cancer	6.87e-06	2.93e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—STAT3—pancreatic cancer	6.87e-06	2.93e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—PTGS2—pancreatic cancer	6.86e-06	2.92e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—EGFR—pancreatic cancer	6.86e-06	2.92e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—PIK3CA—pancreatic cancer	6.86e-06	2.92e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—TGFB1—pancreatic cancer	6.85e-06	2.92e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—NRAS—pancreatic cancer	6.85e-06	2.92e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—EGFR—pancreatic cancer	6.85e-06	2.92e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—EGFR—pancreatic cancer	6.72e-06	2.86e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—PIK3CA—pancreatic cancer	6.67e-06	2.84e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—TP53—pancreatic cancer	6.67e-06	2.84e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—TP53—pancreatic cancer	6.64e-06	2.83e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—HRAS—pancreatic cancer	6.61e-06	2.81e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—KRAS—pancreatic cancer	6.59e-06	2.81e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—PIK3CA—pancreatic cancer	6.57e-06	2.8e-05	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—AKT1—pancreatic cancer	6.55e-06	2.79e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—APOE—pancreatic cancer	6.55e-06	2.79e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Metabolism—AKT1—pancreatic cancer	6.52e-06	2.78e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—KRAS—pancreatic cancer	6.48e-06	2.76e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Metabolism—PIK3CA—pancreatic cancer	6.48e-06	2.76e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—KRAS—pancreatic cancer	6.47e-06	2.75e-05	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—AKT1—pancreatic cancer	6.46e-06	2.75e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—TP53—pancreatic cancer	6.45e-06	2.75e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—MYC—pancreatic cancer	6.38e-06	2.72e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—HRAS—pancreatic cancer	6.38e-06	2.72e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—TGFB1—pancreatic cancer	6.37e-06	2.71e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—TP53—pancreatic cancer	6.35e-06	2.7e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—KRAS—pancreatic cancer	6.35e-06	2.7e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—HRAS—pancreatic cancer	6.35e-06	2.7e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—EGFR—pancreatic cancer	6.24e-06	2.66e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—HRAS—pancreatic cancer	6.17e-06	2.63e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—HRAS—pancreatic cancer	6.07e-06	2.59e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—PIK3CA—pancreatic cancer	6.05e-06	2.58e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—PTEN—pancreatic cancer	5.99e-06	2.55e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—PIK3CA—pancreatic cancer	5.96e-06	2.54e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—PIK3CA—pancreatic cancer	5.94e-06	2.53e-05	CbGpPWpGaD
Paliperidone—CYP3A5—Metabolism—PIK3CA—pancreatic cancer	5.94e-06	2.53e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—PIK3CG—pancreatic cancer	5.91e-06	2.52e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—KRAS—pancreatic cancer	5.9e-06	2.51e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—TP53—pancreatic cancer	5.86e-06	2.49e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—AKT1—pancreatic cancer	5.83e-06	2.48e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—PIK3CA—pancreatic cancer	5.83e-06	2.48e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—TP53—pancreatic cancer	5.76e-06	2.45e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—TP53—pancreatic cancer	5.75e-06	2.45e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—PPARG—pancreatic cancer	5.7e-06	2.43e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—TP53—pancreatic cancer	5.64e-06	2.4e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—AKT1—pancreatic cancer	5.63e-06	2.4e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—AKT1—pancreatic cancer	5.6e-06	2.39e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—HRAS—pancreatic cancer	5.6e-06	2.38e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—HRAS—pancreatic cancer	5.51e-06	2.35e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—HRAS—pancreatic cancer	5.5e-06	2.34e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—AKT1—pancreatic cancer	5.45e-06	2.32e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—PIK3CA—pancreatic cancer	5.42e-06	2.31e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—HRAS—pancreatic cancer	5.4e-06	2.3e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—AKT1—pancreatic cancer	5.36e-06	2.28e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Metabolism—AKT1—pancreatic cancer	5.29e-06	2.25e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—TP53—pancreatic cancer	5.24e-06	2.23e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—PIK3CD—pancreatic cancer	5.2e-06	2.21e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—HRAS—pancreatic cancer	5.01e-06	2.13e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—AKT1—pancreatic cancer	4.95e-06	2.11e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—AKT1—pancreatic cancer	4.87e-06	2.07e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—AKT1—pancreatic cancer	4.86e-06	2.07e-05	CbGpPWpGaD
Paliperidone—CYP3A5—Metabolism—AKT1—pancreatic cancer	4.85e-06	2.07e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—AKT1—pancreatic cancer	4.76e-06	2.03e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—PIK3CB—pancreatic cancer	4.53e-06	1.93e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—PTGS2—pancreatic cancer	4.49e-06	1.91e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—AKT1—pancreatic cancer	4.43e-06	1.89e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—PIK3CA—pancreatic cancer	4.22e-06	1.8e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—PTEN—pancreatic cancer	3.91e-06	1.67e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—AKT1—pancreatic cancer	3.45e-06	1.47e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—PIK3CA—pancreatic cancer	2.76e-06	1.18e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—AKT1—pancreatic cancer	2.26e-06	9.6e-06	CbGpPWpGaD
